Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

The prevailing view of cold tumors as a singular immune-insensitive state is not merely imprecise, which is clinically misleading. Currently, we contend that cold tumors comprise a heterogeneous spectrum of resistance ecosystems by distinct, coexisting, dominant barriers. We argue that a universal "heating" strategy is unlikely to succeed; instead, durable clinical benefit will depend on barrier-directed immune reprogramming. We dissect this heterogeneity by linking a set of core mechanistic drivers to canonical hot, immune‑desert, and immune-excluded phenotypes. The drivers include defective antigen processing and presentation, impaired T-cell priming, physical exclusion by aberrant vasculature, stromal components, metabolic exhaustion, and adaptive resistance. Our evaluation of emerging conversion strategies focuses not on their novelty but on capacity to neutralize a specific rate-limiting barrier. We also examine why combination and sequencing are indispensable, highlight translational gaps between preclinical models and human disease and propose a dynamic biomarker framework that extends beyond static PD-L1 assessment to capture real-time shifts in dominant barrier. Our central conclusion is that durable cold-to-hot conversion will require iterative, biomarker-guided and barrier-adaptive interventions that evolve alongside tumor counter-adaptation. The reframing positions immunotherapy resistance not as a terminal obstacle but as a manageable, dynamic challenge, offering a practical strategy for clinical translation.